Evidence map›Paper›PMID 38205079›Full record

ArticleTherapeutic advances in medical oncology2024

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain.

Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, Juana María Cano Cano, Javier Martínez Trufero, Alberto Rafael Sevillano Tripero, Tania Luis García, Manuel Jorge Cuesta Rioboo and 6 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Jaime Carrillo-GarcíaHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Serena LacerenzaInstitute of Biomedicine of Seville (IBIS), HUVR-CSIC-University of Seville, Seville, Spain.
Nadia HindiHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Irene Carrasco GarcíaMedical Oncology Department, University Hospital Virgen del Rocío, Seville, Spain.
Gloria MarquinaDepartment of Medical Oncology, Hospital Clínico San Carlos, School of Medicine, Complutense University (UCM), IdISSC, Madrid, Spain.
Juana María Cano CanoMedical Oncology Department, University Hospital General de Ciudad Real, Ciudad Real, Spain.
Javier Martínez TruferoMedical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain.
Alberto Rafael Sevillano TriperoMedical Oncology Department, University Hospital General de Villalba, Madrid, Spain.
Tania Luis GarcíaDepartment of Medical Oncology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Manuel Jorge Cuesta RiobooDepartment of Medical Oncology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
David S MouraHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Marta RenshawHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Jose L Mondaza-HernándezHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.ORCID https://orcid.org/0000-0002-5642-3796
Davide Di LerniaHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Antonio GutierrezDepartment of Hematology, University Hospital Son Espases, Palma, Spain.
Javier Martin-BrotoHealth Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Reyes Católicos 2, Madrid 28040, Spain.ORCID https://orcid.org/0000-0001-7350-6916
Hospital Universitario Fundación Jiménez Díaz · ESHospital Clínico San Carlos · ESHospital General Universitario de Ciudad Real · ESHospital Universitario Miguel Servet · ESHospital Universitario Son Espases · ESHospital Universitario Virgen del Rocío · ESInstituto de Biomedicina de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: Social distancing and quarantine implanted during the COVID-19 outbreak could have delayed the accession of oncologic patients to hospitals and treatments. This study analysed the management of sarcoma patients during this period in five Spanish hospitals. Design and methods: Clinical data from adult sarcoma patients, soft tissue and bone sarcomas, managed during the COVID-19 outbreak, from 15 March to 14 September 2020 (Covid cohort), were retrospectively collected and time for diagnosis, surgery and active treatments were compared with sarcoma patients managed during the same pre-pandemic period in 2018 (Control cohort). Results: A total of 126 and 182 new sarcoma patients were enrolled in the Covid and Control cohorts, respectively, who were mainly diagnosed as soft tissue sarcomas (81.0% and 80.8%) and at localized stage (80.2% and 79.1%). A diagnostic delay was observed in the Covid cohort with a median time for the diagnosis of 102.5 days (range 6-355) Conclusion: Delays in diagnosis and surgery were retrospectively observed in sarcoma patients during the COVID-19 outbreak in Spain, while the time for neoadjuvant radiotherapy was reduced. However, no impact on the PFS and OS was observed.

Indexed as

bone sarcomaCOVID-19 outbreakdelay in surgerydiagnostic delaysoft tissue sarcoma

Identifiers

PMID38205079
PMCPMC10777772
OpenAlexW4390730222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.